WuXi Biologics (Cayman) Inc
Company Profile
Business description
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing, refining, and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
Contact
No. 108, Meiliang Road
Mashan Binhu District
Wuxi214092
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13,252
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.80 | 42.20 | 0.47% |
| CAC 40 | 7,882.26 | 34.94 | 0.45% |
| DAX 40 | 25,502.59 | 91.75 | 0.36% |
| Dow JONES (US) | 52,361.58 | 146.42 | 0.28% |
| FTSE 100 | 10,683.90 | 83.43 | -0.77% |
| HKSE | 23,041.32 | 170.49 | -0.73% |
| NASDAQ | 26,169.38 | 214.04 | 0.82% |
| Nikkei 225 | 63,268.37 | 1,078.72 | 1.73% |
| NZX 50 Index | 13,680.27 | 53.66 | -0.39% |
| S&P 500 | 7,676.77 | 53.09 | 0.70% |
| S&P/ASX 200 | 8,850.10 | 40.20 | 0.46% |
| SSE Composite Index | 3,648.30 | 49.22 | -1.33% |